Previous and potential mutations of Sars-cov-2 receptors and their interaction with known inhibitors

SARS-CoV-2, the seventh coronavirus known to infect humans after 229E, NL63, 0C43, HKU1, MERS-CoV, and the original SARS-CoV, has a large positive-stranded RNA genome of 29,891 nucleotides and 9,860 amino acids. It is a strain of coronavirus that causes COVID 19. It was first discovered in the Chinese city of Wuhan. It undergoes several mutations hence posing a great difficulty in finding a suitable inhibitor. This studies previous and potential mutations of Sars-cov-2 receptors and their interaction with known inhibitors. There are four measures to take in generating SARS-CoV-2 inhibitors that might surpass mutation should it arise which includes; a. finding inhibitors with two or more mechanism of inhibition in virus target inhibition b. employing host target inhibition c. complex forming compounds that will interfere with viral-host cell fusion independent of interaction with the host or organism d. human receptor cell lookalikes with higher affinity to the virus (proteins). Employing any of these measures might produce a good inhibitor however, drug resistance may emerge quickly after treatment as a result of the numerous mutations that RNA virus experience but host cell mutations are uncommon, treatments that target the host cells may delay the emergence of drug resistance.